Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | SCN11A | Q9UI33 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655278 | 1.00 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL30492082 | 1.00 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL1630078 | 1.00 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL181178 | 1.00 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL2993610 | 1.00 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL8529811 | 1.00 | SCN1A (0.41) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL6079568 | 0.97 | SCN1A (0.39) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL4748922 | 0.97 | SCN1A (0.39) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL4012058 | 0.97 | SCN1A (0.39) | SCN1ASCN4ASCN7AKCNH2SCN5A | |
| SCHEMBL1814570 | 0.97 | SCN1A (0.42) | SCN1ASCN4ASCN7AKCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560823-B1 | 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2008-07-09 | — | — | EP | claimed |
| EP-4196267-B1 | NOVEL RUTHENIUM COMPLEXES, METHODS OF THEIR PREPARATION AND APPLICATION THEREOF IN OLEFIN CROSS METATHESIS | APEIRON SYNTHESIS SA (PL) | 2023-11-29 | — | — | EP | disclosed |
| US-10233149-B2 | Methods for forming peroxyformic acid and uses thereof | ECOLAB USA INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180093948-A1 | METHODS FOR FORMING PEROXYFORMIC ACID AND USES THEREOF | ECOLAB USA INC. | 2018-04-05 | — | — | US | disclosed |
| EP-1487829-B1 | THIADIAZOLYLPIPERAZINE DERIVATIVES USEFUL FOR TREATING OR PREVENTING PAIN | EURO CELTIQUE SA (LU) | 2007-10-10 | — | — | EP | disclosed |
| EP-0970084-B1 | PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AG (DE) | 2003-06-04 | — | — | EP | disclosed |
| EP-0970084-A1 | PYRROLO 2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-12 | — | — | EP | disclosed |
| US-6001839-A | Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 1999-12-14 | — | — | US | disclosed |
| WO-1998041525-A1 | PYRROLO[2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | disclosed |
| EP-0361341-A2 | Therapeutics for aids based on inhibitors of HIV protease | MILES INC. (US) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233149-B2 | Methods for forming peroxyformic acid and uses thereof | PRDX2, PRDX6, PRDX1 | SCN1A 4174/4885SCN4A 4302/4885SCN7A 3006/4885 |
| US-20180093948-A1 | METHODS FOR FORMING PEROXYFORMIC ACID AND USES THEREOF | PRDX2, PRDX6, PRDX1 | SCN1A 4174/4885SCN4A 4302/4885SCN7A 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.